ArticleNPJ breast cancer2026
Risk factors for second primary cancer in patients who survive breast cancer.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer survivors are living longer. However, the risk of second primary cancer (SPC) remains a concern. The aim of this study was to identify risk factors for synchronous SPC (sSPC) and metachronous SPC (mSPC) among patients who survive breast cancer and evaluate causes of death. This population-based cohort study used data from the South Korean Cancer Public Library Database, which integrates the national cancer registry with insurance claim and health screening data. Female patients diagnosed with primary breast cancer between 2012 and 2019 were included in the study. SPCs were defined as new histologically distinct malignancies occurring six months or more (mSPC) or less than six months (sSPC) after breast cancer diagnosis. Cox proportional hazards models were used to identify risk factors for SPC. Cumulative incidence and causes of death were examined by cancer stage and age. Among 15,430 women with breast cancer who met the eligibility criteria, 497 developed sSPC and 812 developed mSPC. In multivariable models, an age ≥70 vs <40 years was associated with a higher risk of both sSPC (hazard ratio [HR], 3.58; 95% confidence interval [CI], 2.01-6.36; P < 0.001) and mSPC (HR, 3.18; 95% CI, 2.06-4.91; P < 0.001). Fasting blood sugar ≥140 mg/dL was associated with sSPC (HR, 1.61; 95% CI, 1.06-2.45; P = 0.02), but not with mSPC. Cumulative-incidence curves showed a higher prevalence of thoracic and gastrointestinal mSPC in older and lower-income strata, consistent with Cox results. Although smoking was more prevalent in low-income groups, it was not an independent predictor. Cause-of-death analyses indicated that SPCs more often accounted for death in older survivors and in those with early-stage index breast cancer. The results of this study identify metabolic and socioeconomic factors as key predictors of SPC in patients who survive breast cancer. Tailored survivorship strategies are needed for high-risk subgroups, including older patients and those with low incomes or poor metabolic profiles.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.